Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2686989 | e-SPEN Journal | 2013 | 9 Pages |
SummaryBackground & aimsKidney disease requires dialysis or kidney transplantation. No generally applicable therapies to slow progression of renal disease are available. The aim of this study was to characterize Sporosarcina pasteurii (MTCC 1761, Type strain) as an effective probiotic strain for acetaminophen induced uremic patent.MethodsAntibacterial and antioxidative activities, bile salt and pH tolerance, starch and protein digestibility, hydrophobicity, opsonophagocytic assay and antibiotics sensitivity of the strain was performed to investigate its probiotic potentialities. Blood uremic profiles, DNA fragmentation assay of kidney tissue and kidney histological studies were investigated on acetaminophen-induced nephrotoxic rats (Wister strain albino male).Results and discussionThe cell free extract of S. pasteurii showed high in vitro antioxidative property and potential antibacterial activity (average diameter of 6 mm) against some reference enteropathogenes. The strain can survive at highly acidic environment (pH 3.0) and showed bile resistance upto 0.8% (w/v) along with 8% (w/v) salt and 0.8% (w/v) phenol. The strain able to digest starch and milk protein and show medium hydrophobic attachment with non-polar solvent. Bacterial strain completely destroyed in the presence of blood components and sensitive to all tested 20 antibiotics. After oral administration of the strain significantly lowered the level of blood urea, creatinine, and uric acid level and minimized the glomerular necrosis, DNA damage of uremic rats.ConclusionTherefore, the strain S. pasteurii may be exploited as a potent probiotic organism and oral ingestion of bacteria decrease uremic syndrome.